Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America

AUSTIN, Texas, July 9, 2026 – Otsuka ICU Medical LLC today announced plans for an over $500 million expansion to its US IV solutions manufacturing through a new facility and significant upgrades to its existing operations in Austin, Texas. The expansion is expected to enhance long-term supply resiliency and accelerate new product development while positioning the portfolio to support evolving non-DEHP legislation across the North American IV solutions market.

The project will leverage Otsuka Pharmaceutical Factory, Inc.’s long-standing expertise in IV container development and manufacturing quality to support Otsuka ICU Medical LLC’s advancement of non-DEHP IV solutions for the North American market. As part of this initiative, Otsuka ICU Medical LLC will expand its existing 700,000-square-foot Austin manufacturing site with a new 500,000-square-foot facility in Austin to support greater operational flexibility and future innovation across IV solutions and specialty pharmaceutical segments.

This expansion is the first major milestone toward delivering on the commitments made by the joint venture between ICU Medical, Inc. and Otsuka Pharmaceutical Factory America, Inc., a subsidiary of Otsuka Pharmaceutical Factory, Inc., finalized in May 2025. It reflects the partnership’s strategic focus on bolstering North American IV solutions manufacturing and innovation, while complementing existing efforts to obtain long-term FDA approval of select overseas Otsuka manufacturing sites to supplement North American supply as needed.

“This expansion reflects our commitment to long-term growth in a clinically essential market,” said Yoshifumi Fujimoto, chief executive officer of Otsuka ICU Medical LLC. “By strengthening our U.S. manufacturing footprint, expanding non-DEHP capabilities, and introducing innovation, we are enhancing supply reliability for North American customers while positioning ourselves to better support future regulatory and legislative requirements.”

The North American IV solutions market remains highly concentrated, and recent supply chain disruptions—driven by natural disasters and infrastructure constraints—have highlighted the importance of resilient, geographically diversified production. At the same time, healthcare providers are preparing for an evolving regulatory environment, including the transition toward non-DEHP IV solutions containers. This expansion is designed to address both needs: strengthening supply resiliency while supporting future portfolio innovation and market readiness.